Tubular nephrotoxicity during long-term ifosfamide and mesna therapy.
The nephrotoxic effects of ifosfamide were assessed in 18 children and adolescents given cumulative doses of 32-112 g/m2 (1.6 g/m2 per day in sequential 5-day courses) with the uroprotectant mesna (1.2 g/m2 per day). Tubular nephrotoxicity was evaluated by measuring the urinary concentrations of N-acetyl-beta-D-glucosaminidase (NAG), alanine aminopeptidase (AAP), and total protein before and during sequential courses of therapy. Of 15 patients who had normal levels of tubular markers before ifosfamide therapy, only 1 developed a persistent increase in baseline values of the three tubular markers with the sixth course of ifosfamide. Although transient increases in the excretion of these markers were observed during each 5-day course of ifosfamide, the magnitude did not increase over sequential courses in these 15 patients. Of the remaining three patients who had increased NAG levels before ifosfamide therapy, two showed a progressive increase in enzymuria and proteinuria, and serum creatinine concentrations increased in a single patient who had obstructive uropathy. Our data suggest that children with normal renal function can be given large cumulative amounts of ifosfamide in fractionated doses with little risk of progressive clinical nephrotoxicity.
Goren
M P
MP
Department of Pathology and Laboratory Medicine, St. Jude Children's Research Hospital, Memphis, TN 38101.
Pratt
C B
CB
Viar
M J
MJ
D000118:Acetylglucosaminidase / Q000652:urine; D000626:Aminopeptidases / Q000652:urine; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D015415:Biomarkers / Q000032:analysis; D018826:CD13 Antigens; D003404:Creatinine / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000009:adverse effects; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D007684:Kidney Tubules / Q000187:drug effects*; D015080:Mesna / Q000008:administration & dosage / Q000009:adverse effects; D011507:Proteinuria / Q000652:urine; D013997:Time Factors
D015415:Biomarkers; D003404:Creatinine; D000118:Acetylglucosaminidase; D000626:Aminopeptidases; D018826:CD13 Antigens; D015080:Mesna; D007069:Ifosfamide